Sirolimus toxicity and vascular endothelial growth factor release from islet and renal cell lines

Transplantation

Volumn 83, Issue 12, 2007, Pages 1635-1638

  Laugharne, Matthew ^a   Cross, Sarah ^a   Richards, Sarah ^a   Dawson, Charlotte ^a   Ilchyshyn, Laura ^a   Saleem, Moin ^a   Mathieson, Peter ^a   Smith, Richard ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Islet; Podocyte; Rapamycin; Sirolimus; Vascular endothelial growth factor (VEGF)

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; VASCULOTROPIN 165;

ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DIABETOGENESIS; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY CELL; KIDNEY PROXIMAL TUBULE; KIDNEY TRANSPLANTATION; KIDNEY TUBULE CELL; NEPHROTOXICITY; PANCREAS ISLET BETA CELL; PANCREAS TRANSPLANTATION; PODOCYTE; PRIORITY JOURNAL; PROTEIN SECRETION;

ANIMALS; CELL LINE; CELL SURVIVAL; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; KIDNEY; MICE; MICE, INBRED C57BL; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34250815070     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000266555.06635.bf     Document Type: Article

References (36)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230.
2. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060.
3. Senior PA, Paty BW, Cockfield SM, Ryan EA, Shapiro AM. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005; 5: 2318.
4. Andres A, Toso C, Morel P, et al. Impairment of renal function after islet transplantation alone or islet-after-kidney transplantation using a sirolimus/tacrolimus-based immunosupressive regimen. Transpl Int 2005; 18: 1226.
5. Bell E, Cao X, Moibi JA, et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 2003; 52: 2731.
6. Fabian MC, Lakey JR, Rajotte RV, Kneteman NM. The efficacy and toxicity of rapamycin in murine islet transplantation. In vitro and in vivo studies. Transplantation 1993; 56: 1137.
7. Simon JF, Swanson SJ, Agodoa LY, Cruess DF, Bohen EM, Abbott KC. Induction sirolimus and delayed graft function after deceased donor kidney transplantation in the United States. Am J Nephrol 2004; 24: 393.
8. Sartelet H, Toupance O, Lorenzato M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005; 5: 2441.
9. Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005; 353: 2088.
10. Sennesael JJ, Bosmans JL, Bogers JP, Verbeelen D, Verpooten GA. Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 2005; 80: 1578.
11. Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005; 80: 1198.
12. Lieberthal W, Fuhro R, Andry CC, et al. Rapamycin impairs recovery from acute renal failure and: Role of cell cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001; 281: F693.
13. Nielsen FT, Starklint H, Dieperink H. Impaired glomerular and tubular function as a short-term effect of sirolimus treatment in the rat. Am J Nephrol 2005; 25: 411.
14. Pallet N, Thervet E, Le Corre D, et al. Rapamycin inhibits human renal epithelial cell proliferation: Effect on cyclin D3 mRNA expression and stability. Kidney Int 2005; 67: 2422.
15. Straathof-Galema L, Wetzels JF, Dijkman HB, Steenbergen EJ, Hilbrands LB. Sirolimus-associated heavy proteinuria in a real transplant recipient: Evidence for a tubular mechanism. Am J Transplant 2006; 6: 429.
16. Wullschleger S, Loewith R, Hall MN. TOR signalling in growth and metabolism. Cell 2006; 124: 471.
17. Lammert E, Gu G, McLaughlin M, et al. Role of VEGF-A in vascularization of pancreatic islets. Curr Biol 2003; 13: 1070.
18. Lai Y, Schneider D, Kidszun A, et al. Vascular endothelial growth factor increases functional beta-cell mass by improvement of angiogenesis of isolated human and murine pancreatic islets. Transplantation 2005; 79: 1530.
19. Sigrist S, Mechine-Neuville A, Mandes K, et al. Influence of VEGF on the viability of encapsulated pancreatic rat islets after transplantation in diabetic mice. Cell Transplant 2003; 12: 627.
20. Chae HY, Lee BW, Oh SH, et al. Effective glycemic control achieved by transplanting non-viral cationic liposome-mediated VEGF-transfected islets in streptozotocin-induced diabetic mice. Exp Mol Med 2005; 37: 513.
21. Zhang N, Richter A, Suriawinata J, et al. Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. Diabetes 2004; 53: 963.
22. Kim SC, Kim TH, We YM, Park HY, Cho KM, Han DJ. Study for improvement of early implantation and long-term graft survival in pancreatic islet cell transplantation by induction of angiogenesis with gene transfection of vascular endothelial growth factor. Transplant Proc 2003; 35: 486.
23. Cross SE, Richards SK, Clark A, et al. Vascular endothelial growth factor as a survival factor for human islets: effect of immunosuppressive drugs. Diabetologia (in press).
24. Foster RR, Saleem MA, Mathieson PW, Bates DO, Harper SJ. Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am J Physiol Renal Physiol 2005; 288: F48.
25. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003; 4: 147.
26. Mayerhofer M, Aichberger KJ, Florian S, et al. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. Faseb J 2005; 19: 960.
27. Kozawa O, Matsuno H, Uematsu T. Involvement of p70 S6 kinase in bone morphogenetic protein signaling: vascular endothelial growth factor synthesis by bone morphogenetic protein-4 in osteoblasts. J Cell Biochem 2001; 81: 430.
28. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128.
29. Yu Y, Sato JD. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol 1999; 178: 235.
30. Leclerc I, Woltersdorf WW, da Silva Xavier G, et al. Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: Impact on glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab 2004; 286: E1023.
31. Ryan MJ, Johnson G, Kirk J, et al. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 1994; 45: 48.
32. Saleem MA, O'Hare MJ, Reiser J, et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 2002; 13: 630.
33. Richards SK, Parton LE, Leclerc I, Rutter GA, Smith RM. Overexpression of AMP-activated protein kinase impairs pancreatic {beta}-cell function in vivo. J Endocrinol 2005; 187: 225.
34. Wang WY, Whittles CE, Harper SJ, Bates DO. An adenovirus-mediated gene-transfer model of angiogenesis in rat mesentery. Microcirculation 2004; 11: 361.
35. Stewart HJ, Ravanan R, Mathieson PW, Bates DO, Smith RM. Differential roles of CD80 and CD86 in islet transplant rejection. Acta Diabetol 2005; 42: 68.
36. Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004; 10: 964.